A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Learn more about:
Related Clinical Trial
Recurrence After Whipple’s (RAW): Retrospective Cohort Study Investigating Patterns of Cancer Recurrence Following Pancreaticoduodenectomy for Pancreatic Head Malignancy Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care Prospective Evaluation of Biliary Tissue Sampling With ERCP Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). DNA Methylation Biomarker for Diagnosis of Cholangiocarcinoma in Patients With Bile Duct Stricture Liver Cancer Registry Platform Target Rare Cancer Knowledge Neoadjuvant Therapy in Biliary Adenocarcinoma BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours the Impact of Early Palliative Care on the Survival of Locally Advanced and / or Metastatic Cholangiocarcinoma Patients Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors Evaluation of MRI Sequences for Ultra-rapid Acquisition of Bile Ducts Images Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant A Clinical Trial to Evaluate Safety and Efficacy of Endovascualr Denervation in Treatment of Cancer Pain Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Efficacy of Fistulotomy for Biliary Cannulation A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Etomidate vs. Midazolam for Sedation During ERCP Loop-tipped Guidewire in Selective Biliary Cannulation Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm BKM120 in Cancers With PIK3CA Activating Mutations A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT PTFE Stents for Treatment of Malignant Biliary Strictures Irreversible Electroporation of Unresectable Liver Tumors Personal Resilience Empowerment Program Study Radiofrequency Ablation for Biliopancreatic Malignancy Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer In Vitro Models of Liver and Pancreatic Cancer Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter Evaluation of Stereotactic Radiosurgery For Liver Malignancies Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies Accuracy of Endoscopic Ultrasound for Detection of Tumors of the Liver Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD Margin Status After Pancreaticoduodenectomy for Cancer A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer A Study of TRK-950 in Patients With Advanced Solid Tumors Combined HCC-MFCCC Proton Therapy and Bevacizumab for Primary Liver Tumors Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer or Hepatic Metastases Fluorescence QRH-882260 Peptide Imaging in the Bile Duct A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture Unilateral Versus Bilateral Stents for Bismuth Type II and III Malignant Hilar Strictures Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1 In-vivo Biliary Study of KSP/QRH Heptapeptide Dimer MRCP Diagnoses EHCC Better When Combined DWI Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Comparison of Biliary Forceps Biopsy and Brush Cytology Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers Pilot Study of Irreversible Electroporation (IRE) to Treat Metastatic Liver Cancer & Cholangiocarcinoma Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Endobiliary RFA for Unresectable Malignant Biliary Strictures A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Clinical Effect and Safety of PDT and RFA for Unresectable EHCC Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma Trial of IRE in Cholangiocarcinoma Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Cholangiocarcinoma Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection Efficiency Evaluation of Photodynamic Therapy With Photofrin® on Unresectable Type III or IV Cholangiocarcinomas PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer S-1 in Combination With Abraxane in Treating Cholangiocarcinoma Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study Gemcitabine/Oxaliplatin and Photodynamic Therapy in Cholangiocarcinoma Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma Chart Review: Unresectable/Metastatic Cholangiocarcinoma Treated With Irinotecan, Capecitabine and Celecoxib Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma Study Of Intrahepatic Arterial Injection of 90-Y Glass Microspheres for Cholangiocarcinoma Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma Registry Study of Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma Patients Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol Study of Pembrolizumab and Olaparib in Bile Duct Cancer Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma ncRNAs in Exosomes of Cholangiocarcinoma Single Arm Study of RAD001 as Monotherapy in Treatment in Advanced Cholangiocarcinoma Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma

Brief Title

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Official Title

A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Brief Summary

      This is an open label, multi-center, phase II study of BBI503 administered to adult patients
      with advanced hepatobiliary cancer who have exhausted all currently approved standard
      anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous
      28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no
      longer clinically benefiting from therapy.

      Safety, efficacy and tolerability of BBI503 will be assessed for the duration of study
      treatment.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Disease Control Rate (DCR)

Secondary Outcome

 Objective response rate (ORR)

Condition

Hepatocellular Carcinoma

Intervention

BBI503

Study Arms / Comparison Groups

 BBI503
Description:  BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

45

Start Date

February 2015

Completion Date

December 2020

Primary Completion Date

February 19, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Signed written informed consent must be obtained and documented according to
             International Conference on Harmonisation (ICH) - Good Clinical Practice (GCP), the
             local regulatory requirements, and permission to use private health information in
             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior
             to study-specific screening procedures

          -  Histologically or cytologically confirmed hepatocellular carcinoma or
             cholangiocarcinoma, that is metastatic, unresectable, or recurrent; and for which no
             currently approved, standard anti-cancer treatment option is available. Patients must
             have received standard of care treatment prior to enrollment.

          -  ≥ 18 years of age

          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
             1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Male or female patients of child-producing potential must agree to use contraception
             or avoidance of pregnancy measures during the study and for 30 days after the last
             BBI503 dose

          -  Females of childbearing potential must have a negative serum pregnancy test

          -  Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 5.0x the upper limit of
             normal (ULN)

          -  Hemoglobin > 8.0 g/dL

          -  Total bilirubin ≤ 2.5 x ULN

          -  Creatinine ≤ 1.5 x ULN or creatinine clearance > 50 mL/min according to the
             Cockcroft-Gault estimation.

          -  Absolute neutrophil count ≥ 1.5 x 10^9/L

          -  Platelets ≥ 60 x 10^9/L

          -  Life expectancy ≥ 3 months

          -  A patient with hepatocellular carcinoma (HCC) which has arisen out of any medical
             context must also meet the following criteria:

          -  Must not be a candidate for potentially curative resection

          -  Must be Child-Pugh class A or B7 (i.e., in order to be eligible, the total Child-Pugh
             score for a patient must be ≤ 7)

          -  Must have received prior treatment with sorafenib; and have had either disease
             progression during treatment or have had documented intolerance to sorafenib such that
             further treatment with sorafenib is not possible.

          -  Patients with uncontrolled massive ascites or presence of hepatic encephalopathy
             within four (4) weeks of first dose are excluded

          -  A patient with confirmed cholangiocarcinoma of any type must also meet the following
             criteria:

          -  Must have disease which is not amenable to surgical, radiation, or combined modality
             therapy with curative intent

          -  Must have received prior treatment with gemcitabine, either alone or in combination
             with a platinum agent. Patients who are not eligible for gemcitabine must have
             received an alternate first-line systemic chemotherapy regimen

        Exclusion Criteria:

          -  Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents
             within 7 days of first dose of BBI503. Patients may begin BBI503 on a date determined
             by the investigator and medical monitor for the sponsor provided there is a minimum of
             7 days since last receiving anti-cancer treatment, and that all prior
             treatment-related adverse events (AEs) have resolved or have been deemed irreversible.

          -  Major surgery within 4 weeks prior to first dose (requiring general anesthesia and/or
             inpatient hospitalization for recovery).

          -  Any known symptomatic or untreated brain metastases requiring increase of steroid dose
             within 2 weeks prior to starting on study. Patients with treated brain metastases must
             be stable for 4 weeks after completion of that treatment. Patients must have no
             clinical symptoms from brain metastases and must be either off steroids or on a stable
             dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with
             known leptomeningeal metastases are excluded, even if treated.

          -  Pregnant or breastfeeding

          -  Significant gastrointestinal disorder(s), in the opinion of the treating investigator,
             (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine
             resection); such that absorption of oral medications may be impaired.

          -  Unable or unwilling to swallow BBI503 capsules daily

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, clinically significant non-healing or healing wounds, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant
             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled
             infection or psychiatric illness/social situations that would limit compliance with
             study requirements (e.g. no reliable transportation).

          -  Subjects with history of another primary cancer, with the exception of: a) curatively
             resected non-melanoma skin cancer; b) curatively treated cervical carcinoma in situ;
             or c) other primary solid tumor with no known active disease present in the opinion of
             the investigator will not affect patient outcome in the setting of current
             hepatobiliary malignancy.

          -  Abnormal ECGs which are clinically significant such as QT prolongation - QTc > 480
             msec, clinically significant cardiac enlargement or hypertrophy, new bundle branch
             block, or signs of active ischemia. Patients with evidence of prior infarction who are
             New York Heart Association (NYHA) functional class II, III, or IV are excluded, as are
             patients with marked arrhythmia such as Wolff Parkinson White pattern or complete
             atrioventricular (AV) dissociation.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT02232633

Organization ID

BBI503-205b

Secondary IDs

BBI503-205HCC

Responsible Party

Sponsor

Study Sponsor

Sumitomo Dainippon Pharma Oncology, Inc


Study Sponsor

, , 


Verification Date

July 2020